PLAINSBORO, N.J. and CANTON, Mass., Jul 15, 2009 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it has signed an agreement with Organogenesis, Inc., to distribute Organogensis' FortaFlex(R) Technology as Inforce(TM) Reinforcement Matrix. FortaFlex(R) has received 510(k) clearance from the United States Food and Drug Administration (FDA), and was the first collagen based biomaterial to be cleared for reinforcement of all tendons of the human body. Integra will feature the Inforce(TM) Reinforcement Matrix at the 25th Annual Summer Meeting of the American Orthopaedic Foot & Ankle Society, July 15-18, 2009, Vancouver, BC, Canada.

"Inforce(TM) Reinforcement Matrix, with FortaFlex(R) Technology, is an excellent complement to our family of tendon protection products that includes our innovative TenoGlide(R) technology. It will be a significant addition to the clinical armamentarium for our upper and lower extremity surgeon customers," said Robert Paltridge, President of Integra Extremity Reconstruction. "This product also fits perfectly within our tendon and nerve repair disease-state focus."

"After a careful selection process for licensing this exceptional technology, we are very pleased to partner with Integra, which has a longstanding and proven track record in successfully launching innovative collagen biomaterials for tissue repair and regeneration," said Dario Eklund, Vice President Bio-surgery and Bio-aesthetics for Organogenesis, Inc.

The Inforce(TM) Reinforcement Matrix is a biological implant with high bio-mechanical strength that may be used for any type of tendon injury that requires surgical reconstruction, and provides a durable reinforcement during the healing phase of a repaired tendon. The Inforce(TM) matrix is composed of biocompatible Type I collagen matrix, designed to provide an environment for host-tissue regeneration and integration of the implant at a controlled rate of in situ remodeling. The matrix is purified to remove non-collagenous materials that may cause inflammatory or immunological responses. The Inforce(TM) matrix is a ready-to-use product, delivered hydrated and requiring no special handling or storage.

Tendon and ligament injuries are some of the most common musculoskeletal disorders, ranging from a mild ankle sprain to an Achilles tendon rupture or flexor tendon injury of the hand. Industry sources estimate that there are approximately 700,000 tendon and ligament repair procedures in the U.S., representing a $1.2 billion market.

The Inforce(TM) Reinforcement Matrix will be sold by Integra's Extremity Reconstruction sales organization, which focuses on lower extremity fixation, upper extremity fixation, tendon protection, peripheral nerve repair/protection and wound repair.

About FortaFlex(R) Technology

FortaFlex(R) Technology is based on proprietary purification and processing methods, making it one of the cleanest collagen biomaterials on the market. By controlling the chemical and physical properties of the material, FortaFlex(R) Technology is tailored for specific surgical needs.

About Organogenesis, Inc.

Massachusetts based Organogenesis, Inc. is a world leading regenerative medicine company focused in the areas of bio-active wound healing, oral regeneration and bio-surgery. The company's mission is to bring the medical marvel of regenerative medicine products to patients and to standardize their use in everyday medical care. For more information, visit www.organogenesis.com.

About Integra Life Sciences

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. Integra's products are used primarily in neurosurgery, orthopedics and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. For more information, visit www.Integra-LS.com

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of FortaFlex(R) Technology and Inforce(TM) Reinforcement Matrix. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2008 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART-P

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.; Organogenesis, Inc.

Integra LifeSciences Holdings Corporation
          Gianna Sabella, Director of Corporate Communications
          (609) 936-2389
          gsabella@integra-LS.com

          Organogenesis, Inc.
          Angelyn Lowe
          (858) 273-1805
          alowe@chasepr.com

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX